Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON45251
NL-OMON45251
Not yet recruiting
Not Applicable

Comparing tumour heterogeneity in primary tumour, circulating tumour cells and its metastases - CTC Autopsy study

niversitair Medisch Centrum Groningen0 sites50 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionslungcancer1002765510029107

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
lungcancer
Sponsor
niversitair Medisch Centrum Groningen
Enrollment
50
Status
Not yet recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Observational non invasive

Investigators

Eligibility Criteria

Inclusion Criteria

  • •1\. Patients with a histologically/cytologically proven lung cancer.
  • •2\. Patients have to have a non\-curable disease state, without curative treatment options
  • •3\. Signed informed consent of patient
  • •4\. Patients family has asserted their acceptance of the patients participation

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials

Unknown
Not Applicable
Comparing tumour heterogeneity in primary tumour, circulating tumour cells and metastasesSCLC niet kleincellig longcarcinoom, longkankerlungcancer, tumour heterogeneity, tumor heterogeniteit, CTC, circulating tumour cell, circulerende tumor cel
NL-OMON29203niversity Medical Centre Groningen30
Recruiting
Not Applicable
Characterisation of tumour heterogeneity and identification of adaptive resistance mechanisms of metastatic castration-resistant prostate carcinomaC61Malignant neoplasm of prostate
DRKS00028021Klinik für Nuklearmedizin am Universitätsklinikum Augsburg45
Not yet recruiting
Phase 1/2
Tumour heterogeneity studies based on dedicated breast PET using proliferation radiotracers: early detection of the treatment response.
2024-512152-38-00Fundacion Instituto De Investigacion Sanitaria De Santiago De Compostela100
Not yet recruiting
Not Applicable
Fluorodeoxyglucose (FDG) and human epidermal growth factor receptor 2 (HER2) positron emission tomography (PET) scan in breast cancerBreast cancerCancer - Breast
ACTRN12624000918527Fiona Stanley Hospital10
Recruiting
Not Applicable
Value of 7 Tesla in gliomasHigh grade and low grade glioma
NL-OMON24352Medical Delta25